Contact Lenses Articles & Analysis: Older
15 news found
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
Due to the aging population, the increase in the widespread use of electronic screens (especially during the COVID-19 pandemic), the prolonged use of contact lenses, and the increasing frequency of myopia laser surgery, the global dry eye population has risen rapidly in recent years, especially amongst younger age groups. ...
The poster spotlights the results of the company’s SIGHT-1 Phase 2a clinical study and its inclusion in this meeting confirms the high level of interest in the eye care industry in drug delivery contact lenses. The SIGHT-1 study demonstrated the safety and tolerability of the company’s lead asset, LL-BMT1, a weekly medicated contact ...
Other risk factors include aging, eye surgeries, dry environments, long-term wearing of contact lenses, and autoimmune diseases. Unlike current treatments,?BRM421 is a novel, first-in-class regenerative peptide therapy which, if successful, could offer patients full relief of symptoms plus repair the damage to the cornea. ...
That study demonstrated the safety and tolerability of the Company’s lead asset, LL-BMT1, a weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. ...
” More specifically, the testing range of T,C&A Lab encompasses the following: l Repair materials for the skeletal-muscle system such as bones, teeth, joints, and tendons l Soft tissue materials such as skin, esophagus, respiratory tract, bladder and other l Cardiovascular system materials such as artificial heart valves, blood vessels, and cardiovascular catheters l Medical ...
The use of contact lenses as ocular drug delivery systems was first introduced as an idea decades ago. As contact lenses have advanced, the once-futuristic thought of drug-delivery contact lenses is now becoming a reality. This article discusses how improvements in contact ...
The new corporate logo was designed to better reflect and illustrate the purpose and passion underlying the Company’s goal to use the MediPrint process to help protect sight by printing ophthalmic drugs on the surface of contact lenses. Additionally, the new web site is www.mediprintlens.com. ...
The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. ...
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces enlightening findings from its primary market research with optometrists and ophthalmologists related to contact lens drug delivery and its proprietary pipeline of assets. Key learnings ...
In SIGHT-1, MediPrint Ophthalmics’ lead asset, LLT-BMT1, a drug-eluting contact lens to treat glaucoma, was administered to five (5) patients in a trial designed following discussions with the FDA. The study subjects, whose average age was 77.4 years old and who had not previously worn contact lenses, wore an LLT-BMT1 lens in each eye for ...
Mojo Vision is developing Mojo Lens, the first true smart contact lens. Menicon is the only company of its kind in the world that is dedicated to all areas of contact lens-related business, including material development, lens designing, manufacturing of lenses and care solutions. ...
CIS Pharma has successful up-scaled the production of its novel contact lens multipurpose and disinfection solution (MPDS) to an industrial setup. The contact lens care solution achieved excellent performance compared to products that are leading the markets. ...
SAN DIEGO, CA, USA (BUSINESS WIRE June 23, 2020) – Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL- BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat ...
Topics include safety glasses, prescription & contact lenses, goggles & face shields, laser & welding protection, and basic eye safety precautions. ...